02 July 2026
02 July 2026
The introduction of Model 2 into Europe aims to support Hyperfine’s international commercial objectives.
Namodenoson showed a tolerable safety profile consistent with previous studies.
Combining whole genome data with AimedBio’s drug development approach is expected to speed up clinical development.
Topline results from RISE3 are expected in H2 2026.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
